SARS-CoV-2 infections in melanoma patients treated with PD-1-inhibitors- a survey of the German ADOREG melanoma registry.

Currently, a second dramatic upsurge of SARS-CoV-2 infection rates is observed across Europe and there is an urgent need to clarify the imminent risk for our melanoma patients under immune checkpoint inhibition (ICI). To this aim we reviewed the clinical course of disease for all patients included in the registry of the German working group of dermato-oncology (ADOreg, www.hautkrebsregister.de) database with confirmed SARS-CoV-2 infection.

Source: European Journal of Cancer - November 28, 2020 Category: Cancer & Oncology Authors: Rose K.C. Moritz, Ralf Gutzmer, Lisa Zimmer, Friedegund Meier, Misbah S. Ahmed, Sabine Sell, Max Schlaak, Florian Kapp, Michael M. Sachse, Sebastian Haferkamp, Julia Welzel, Katharina K ähler, Michael Weichenthal Tags: Letter to the Editor Source Type: research